Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||
| Earning before tax | ---- | 5.97%180.18M | ---- | 55.07%170.03M | --58.62M | -27.05%109.64M | -14.46%150.3M | --175.7M |
| Profit adjustment | ||||||||
| Revaluation surplus: | ---- | 28.10%-110K | ---- | ---153K | ---134K | ---- | ---- | ---- |
| -Other fair value changes | ---- | 28.10%-110K | ---- | ---153K | ---134K | ---- | ---- | ---- |
| Asset sale loss (gain): | ---- | 104.62%133K | ---- | 41.30%65K | --13K | 119.05%46K | -95.66%21K | --484K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | 104.62%133K | ---- | 41.30%65K | --13K | 119.05%46K | -95.66%21K | --484K |
| Depreciation and amortization: | ---- | 5.94%73.54M | ---- | 48.43%69.41M | --33.27M | 134.01%46.77M | 30.73%19.99M | --15.29M |
| -Amortization of intangible assets | ---- | 6.67%2.53M | ---- | 15.61%2.37M | --1.11M | 0.00%2.05M | -41.53%2.05M | --3.51M |
| Financial expense | ---- | -12.55%26.48M | ---- | 27.54%30.29M | --15.84M | 135.74%23.75M | -24.92%10.07M | --13.42M |
| Operating profit before the change of operating capital | ---- | 3.92%280.22M | ---- | 49.63%269.64M | --107.61M | -0.10%180.2M | -11.96%180.38M | --204.89M |
| Change of operating capital | ||||||||
| Inventory (increase) decrease | ---- | -91.22%1.38M | ---- | 123.91%15.7M | ---11.62M | -383.03%-65.65M | -149.31%-13.59M | --27.57M |
| Accounts receivable (increase)decrease | ---- | 44.19%-98.12M | ---- | 33.79%-175.82M | ---52.23M | -1,493.74%-265.56M | 197.45%19.05M | ---19.55M |
| Accounts payable increase (decrease) | ---- | -79.91%9.79M | ---- | 21.08%48.7M | --11.23M | -60.35%40.22M | 3,026.01%101.44M | --3.25M |
| Special items for working capital changes | ---- | -92.49%2.17M | ---- | 113.42%28.86M | --18.07M | 394.04%13.52M | 131.75%2.74M | --1.18M |
| Cash from business operations | 121.09%98.03M | 4.46%195.44M | -39.32%44.34M | 292.33%187.08M | --73.07M | -133.54%-97.27M | 33.45%290.02M | --217.32M |
| Other taxs | -37.32%-18.85M | -22.50%-28.66M | -33.45%-13.73M | 6.30%-23.39M | ---10.29M | 9.29%-24.96M | 26.64%-27.52M | ---37.52M |
| Net cash from operations | 158.65%79.18M | 1.89%166.78M | -51.24%30.61M | 233.92%163.69M | --62.78M | -146.57%-122.23M | 45.99%262.49M | --179.81M |
| Cash flow from investment activities | ||||||||
| Interest received - investment | 44.76%414K | -28.10%110K | --286K | --153K | ---- | ---- | ---- | ---- |
| Sale of fixed assets | ---- | 100.00%126K | ---- | -98.77%63K | --49K | 1,790.37%5.1M | 527.91%270K | --43K |
| Purchase of fixed assets | -37.72%-59.48M | -37.30%-96.08M | 11.63%-43.19M | 74.81%-69.98M | ---48.87M | 52.50%-277.83M | -289.93%-584.88M | ---150M |
| Purchase of intangible assets | ---- | 97.77%-485K | ---- | ---21.78M | ---12.07M | ---- | -7,924.50%-32.1M | ---400K |
| Recovery of cash from investments | 99.59%40M | 50.00%90M | -60.02%20.04M | --60M | --50.13M | ---- | ---- | ---- |
| Cash on investment | ---- | -116.67%-130M | 66.67%-20M | ---60M | ---60M | ---- | ---- | ---- |
| Other items in the investment business | ---- | ---- | ---- | ---- | ---- | ---- | --39.51M | ---- |
| Adjustment items of investment business | ---540K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash from investment operations | 54.26%-19.61M | -48.93%-136.33M | 39.43%-42.86M | 66.43%-91.54M | ---70.77M | 52.75%-272.72M | -283.89%-577.2M | ---150.35M |
| Net cash before financing | 586.50%59.58M | -57.80%30.45M | -53.40%-12.25M | 118.27%72.15M | ---7.98M | -25.50%-394.96M | -1,168.51%-314.71M | --29.45M |
| Cash flow from financing activities | ||||||||
| New borrowing | -58.18%118.35M | -2.33%665.21M | 20.90%283M | -19.40%681.06M | --234.07M | 11.18%845.01M | 181.51%760.07M | --270M |
| Refund | 62.10%-103M | 17.16%-693.79M | 24.91%-271.75M | -69.44%-837.56M | ---361.9M | -78.47%-494.32M | 22.74%-276.98M | ---358.52M |
| Interest paid - financing | 43.35%-7.78M | 18.95%-25.82M | 20.67%-13.73M | -5.13%-31.86M | ---17.31M | -76.82%-30.31M | -29.46%-17.14M | ---13.24M |
| Dividends paid - financing | ---98.58M | ---- | ---- | -27.15%-29.83M | ---- | 52.50%-23.46M | -82.36%-49.39M | ---27.09M |
| Absorb investment income | --406.29M | ---- | ---- | 1,110.74%207.64M | --207.64M | -0.29%17.15M | -58.86%17.2M | --41.81M |
| Issuance expenses and redemption of securities expenses | -147.75%-15.18M | -76.11%-7.79M | ---6.13M | ---4.43M | ---- | ---- | ---- | ---- |
| Other items of the financing business | ---- | ---- | ---- | ---19.76M | ---15.51M | ---- | -4.75%-3.95M | ---3.77M |
| Net cash from financing operations | 2,987.51%298.63M | -72.38%-65.17M | -123.06%-10.34M | -112.10%-37.8M | --44.85M | -27.05%312.41M | 569.99%428.24M | ---91.12M |
| Other items affecting net cash | --540K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net Cash | 1,688.20%358.74M | -201.08%-34.72M | -161.26%-22.59M | 141.61%34.35M | --36.87M | -172.71%-82.55M | 284.11%113.53M | ---61.66M |
| Begining period cash | -20.90%131.39M | 26.07%166.1M | 26.07%166.1M | -38.52%131.76M | --131.76M | 112.66%214.31M | -37.96%100.78M | --162.44M |
| Cash at the end | 241.52%490.13M | -20.90%131.39M | -14.89%143.52M | 26.07%166.1M | --168.63M | -38.52%131.76M | 112.66%214.31M | --100.78M |
| Cash balance analysis | ||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |
| Auditor | -- | KPMG | -- | KPMG | -- | KPMG | PwC accounting firm | PwC accounting firm |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.